ロード中...
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
BACKGROUND: In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring methods compar...
保存先:
| 出版年: | Breast Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7310491/ https://ncbi.nlm.nih.gov/pubmed/32576238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01303-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|